신규 진단된 만성기 만성 골수성 백혈병에 대한 이마티닙과 인터페론 및 저용량 시타라빈의 비교

O’Brien 등(목요일)이 이 문제를 연구했다.

www.synapsesocial.com/papers/6985f297db3aef8684169ecd — DOI: https://doi.org/10.1056/nejmoa022457

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia· 2001 · 5,234 citations
2. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study· 2002 · 1,030 citations
3. Staging and prognosis in chronic myelogenous leukemia.· 1988 · 214 citations
4. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.· 1996 · 1,080 citations
5. Randomized Study on Hydroxyurea Alone Versus Hydroxyurea Combined With Low-Dose Interferon-α2b for Chronic Myeloid Leukemia· 1998 · 54 citations